During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss the challenges clinicians face when developing a drug-sequencing plan for patients with castration-resistant prostate cancer.
Dr Quinn explains that because not all patients respond to the same types of therapy, there is a need for data that reveals the appropriateness of agents suggested in step therapy plans.
To address this challenge, he suggests that new clinical trials test comparative effectiveness, which he believes can help determine response rates for specific groups of patients.
Dr Kolodziej argues that receiving this data will take too long, and suggests receiving aid from professional services that can structure current data into an actionable format. He explains that this may help provide quick answers about step therapy and can improve the clinician’s decision-making process.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization
March 7th 2025A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.
Read More